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Abstract Smoking is the main causative factor for
development of head and neck and lung cancer. In addition,
other malignancies such as bladder, stomach, colorectal,
kidney and pancreatic cancer have a causative relation with
smoking. Continued smoking after having been diagnosed
with cancer has many negative consequences: effectiveness
of radiotherapy is diminished, survival time is shortened
and risks of recurrence, second primary malignancies and
treatment complications are increased. In view of the sig-
niﬁcant health consequences of continued smoking, there-
fore, additional support for patients to stop smoking seems
a logical extension of the present treatment protocols for
smoking-related cancers. For prospectively examining the
effect of nursing-delivered smoking cessation programme
for patients with head and neck or lung cancer, 145 patients
with head and neck or lung cancer enrolled into this
programme over a 2-year period. Information on smoking
behaviour, using a structured, programme speciﬁc ques-
tionnaire, was collected at baseline, and after 6 and
12 months. At 6 months, 58 patients (40%) had stopped
smoking and at 12 months, 48 patients (33%) still had
refrained from smoking. There were no differences in
smoking cessation results between patients with head and
neck and lung cancer. The only signiﬁcant factor predicting
success was whether the patient had made earlier attempts
to quit smoking. A nurse-managed smoking cessation
programme for patients with head and neck or lung cancer
shows favourable long-term success rates. It seems logical,
therefore, to integrate such a programme in treatment
protocols for smoking-related cancers.
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Introduction
Tobacco use in the form of cigarette, pipe or cigar smoking
is associated with 5 million deaths per year worldwide. The
estimation for 2025 is that this number will increase to
10 million deaths annually [1]. Furthermore, there appears
to be a synergistic effect between smoking and alcohol
intake. The relative risk of developing, for example,
supraglottic laryngeal cancer is increased by 50% from
what would be predicted by the simple additive effect of
tobacco and alcohol abuse combined [2].
Smoking is the main causative factor for the develop-
ment of head and neck and lung cancer. In addition, other
malignancies, such as bladder, stomach, colorectal, kidney
and pancreas cancer, have a causative relation with
smoking [1, 3–5]. In the Netherlands, although a decline
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population is still smoking.
To continue smoking after having been diagnosed with
cancer has many negative consequences: the effectiveness
of radiotherapy is diminished, survival time is shortened,
and the risks of recurrence, second primary malignancies
and treatment complications are increased. In a recent
study from the Netherlands comprising 2012 patients, the
effects of continued smoking on recurrence rate, secondary
cancers, and on mortality was clearly shown (see Table 1)
and the authors rightfully emphasise the importance of
substance abuse cessation [6]. In a case–control study in
202 patients, Chen et al. [7] conﬁrmed that tobacco
smoking during radiation therapy for head-and-neck cancer
was associated with unfavourable outcomes. Obviously,
these complications and side effects also have a negative
impact on the patient’s quality of life. Nevertheless, many
patients, who were smoking prior to their illness, continue
after diagnosis and treatment [8].
Although clinicians often warn about these smoking-
related consequences and already at the time of diagnosis
recommend their cancer patients to quit smoking, reports
indicate that still 35–72% of patients continue smoking
during and after treatment [9, 10]. Positively interpreted,
these data indicate that fortunately, many smokers are able
to stop without help and physicians and other health-care
professionals apparently to some extent still have a positive
inﬂuence on smoking cessation. This approach has reported
threefold to ﬁvefold increased cessation rates [11–13].
Furthermore, research has shown that patients suffering
from serious disease may be more open for smoking ces-
sation advice than smokers without serious health problems
[14]. This means that patients receiving the diagnosis
‘‘cancer’’ probably are more receptive for such advise by
their physician, and if that does not work, for an additional
counselling programme. Better than in an initial patient-
physician contact, such a counselling programme more
comprehensively can and should be targeted towards
dealing with the physical addiction to nicotine, the psy-
chological reliance on the effects of nicotine, and the
behavioural aspects of tobacco use [11].
In view of these signiﬁcant health consequences of
continued smoking, we considered that additional support
for patients to stop smoking should become an integral part
of the treatment protocol for those cancers that are clearly
smoking related. For this reason, a ‘stop smoking clinic’
was initiated in the Netherlands Cancer Institute. In this
paper, we assess whether such a clinic can contribute to
smoking cessation in the patient population, who did not
succeed in stopping solely on the basis of counselling by
the health-care providers before the onset of their onco-
logic treatment. We will present the outcomes of this ini-
tiative with emphasis on the 12-month follow-up results
and provide some data on the costs of the programme.
Patients and methods
Patients
The project started as a so-called ‘Care-renewal project’
endorsed and funded by the health-care authorities and the
study has been performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
From November 2003 to December 2005, 185 patients
visiting the hospital were referred to the ‘stop smoking
clinic’. There were 16 patients who were excluded from the
programme as they did not have cancer, and 24 patients,
after having been informed about the programme, decided
they did not (yet) want to participate, resulting in 145
patients for further enrolment in the programme, 78 (54%)
males and 67 (46%) females. Of these patients, the
majority had head-and-neck cancer (N = 96, 66%), fol-
lowed by lung cancer (N = 34, 24%) and various other
cancers (N = 15, 10%; breast cancer, sarcoma, or bladder
cancer). The mean age patients started to smoke was
15 years, the mean consumption was 20 cigarettes per day
and the mean tobacco exposure was 45 pack/years. All data
were collected prospectively. Further detailed characteris-
tics of the patients enrolled in the cessation programme are
shown in Table 2. Patients were able to start with the
programme at any time of their treatment, resulting in 45
patients (31%) starting the programme pre-treatment, (29)
20% during, and 71 (49%) post-treatment.
Counselling methods
The intervention programme applied is founded on the self-
efﬁcacy theory of Bandura, which is based on the patient’s
self-efﬁcacy (conﬁdence in succeeding) and the changing
model of Prochaska and DiClemente [15, 16]. We followed
the seven steps of the Minimal Intervention Program of
Stivoro (government organisation for stopping smoking in
the Netherlands; http:\\www.stivoro.nl).
Table 1 Probabilities of recurrence, secondary tumours and mor-
tality, as derived from the Dutch study by Fadharspour, comprising
2012 patients with head-and-neck cancer [6]
Rates per year Mean
Recurrence rate for non-smokers 0.048
Recurrence rate for smokers 0.064
Secondary cancer for non-smokers 0.062
Secondary cancer for smokers 0.082
Mortality rate for non-smokers 0.013
Mortality rate for smokers 0.014
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sists of seven steps engaging the patients to stop smoking
[17].
1. Physician’s advice about the necessity to stop
smoking.
2. Data collection regarding smoking status by means of
a structured questionnaire.
3. Motivational interviewing of the patient to stop
smoking.
4. Inventory of barriers in the stop smoking period.
5. Information about smoking cessation.
6. Fixing a stop smoking date.
7. Arrangement of follow-up and support.
The programme is most intensive in the ﬁrst month, and
lasts in total 1 year, in order to support the patient through
several (annual) risk situations such as birthdays, stress
situations and holidays. Detailed information (timetable)
about the programme is shown in Table 3.
Since, in combination with alternative nicotine products
(ANP), counselling appears to be an effective strategy to
stop smoking, different products (nicotine lozenges, bu-
proprion and combinations of products) were offered as
well [17].
Cost assessment
The average counselling time needed for the one-year
programme was assessed on the basis of the schedule
applied and the costs of the counselling time by the
specialists-nurse were calculated using the report of Ha-
kkaart-van Roijen et al.; the costs for the nicotine
replacements were derived from the Pharmacotherapeutic
Compass (http://www.fk.cvz.nl/, nicotine replacements)
[18, 19].
Statistical analyses
Data were entered into an SPSS database (version 15.0);
the analysis is mainly descriptive. Differences are mea-
sured with the Chi square or the Fisher exact test, while
differences between continuous variables have been
measured by the Wilcoxon test (effect and results) or the
Kruskal–Wallis test (months). Differences between the
patient groups are measured by the Mantel–Heanszel
test. A p value \0.05 was considered statistically
signiﬁcant.
Table 2 Patient characteristics (n = 145)
Gender
Male 78 (54%)
Female 67 (46%)
Age (mean) 55.7 years (range 36–77 years)
Smoking data
Age at start of smoking (mean) 15.8 years (range 9–25 years)
Years of smoking (mean) 39 years (range 18–58 years)
Pack years (mean) 45 (range 3–154)
Daily number of cigarettes (mean) 20 (range 2–70)
Tumour site
Head and neck 96 (66%)
Lung 34 (24%)
Other cancer sites 15 (10%)
Timing of enrolment
Pre-treatment 45 (31%)
During treatment 29 (20%)
Post-treatment 71 (49%)
Table 3 Timetable counselling programme
Visit Duration
Intake 1 h Complete structured questionnaire with smoking-related questions
Education about effects of tobacco use (especially in relation to their disease)
Education about how to stop smoking and avoid a relapse
Information about nicotine replacements (the choice of medication is usually based on the patients
preference, drug cost and previous experience)
Determine a stop smoking date
Once a week (during ﬁrst
month)
10–20 min Evaluate the stop smoking period
Information about how to avoid a relapse
Every other month
a, but at
least at 6 month
10–20 min Evaluate the stop smoking period
Information about how to avoiding a relapse
Information about reducing/ending the nicotine replacements
12 months 10–20 min Endpoint of the stop smoking counselling
Completing evaluation form
a Depending on the patients needs and travel times
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At 6 months, 58 patients (40%) had stopped smoking, 79
patients (54%) were still smoking, and 8 patients (6%)
were lost to follow-up. After 12 months, 48 patients (33%)
still had refrained from smoking, 60 patients (41%) had
continued or were smoking again and 37 patients (26%)
were ‘lost to follow-up’. Of these 37 patients, 5 died of
disease, 13 had a recurrence, and 19 patients did not return
for their one-year appointment (see Table 4). Of the 98
head-and-neck cancer patients, 30 (31%) and of the 32 lung
cancer patients, 10 patients (31%) stopped smoking. Of the
60 patients, who did not quit smoking, 24 patients (22%)
reported that they had reduced their number of cigarettes
per day with 50% or more. No statistically signiﬁcant
effect with regards to the initial enrolment into the pro-
gramme, i.e. pre-, during, or post-treatment, could be
found: after 12 months, the number of patients in each of
these three groups, who actually had stopped, was 13, 17
and 18 patients, respectively (p = 0.236). There was also
no correlation of alcohol intake on the cessation rate
(p = 0.588). Previously having tried to quit smoking,
however, appeared to have a statistically signiﬁcant posi-
tive inﬂuence. Patients, who had made earlier attempts to
stop before entering into this programme, showed better
smoking cessation results (n = 33, 69%) than patients,
who never had tried to stop (n = 14, 29%, p\0.05; data
of one patient missing). There were no other statistical
signiﬁcant predictors for success, such as the motivation
status of the patient at the start of the programme (assessed
with a single question in the structured questionnaire,
combining the answers a little to very motivated). In
addition, no statistically signiﬁcant association between the
use of nicotine replacement products and smoking cessa-
tion could be established. During the 12-month pro-
gramme, 91 of the 108 patients (84%) used some kind of
nicotine replacement; the 12-month follow-up data are
available (see Table 5). Furthermore, the data did not show
an association between alcohol use and smoking cessation.
Finally, neither the behaviour of the partner of the patient
with respect to his/her own smoking (stopping or contin-
uing), nor the extent of support by family and/or friends did
appear to signiﬁcantly affect the results.
This smoking cessation programme continued following
our initial 2-year study period, and in Table 6 an overview
is given of the number of since then included patients and
their 12-month results. Although not further statistically
analysed, it can be seen that except for 2006, when there
was a dip in patients, stafﬁng and experience with the
programme, results are actually fairly constant, with 36%
1-year success in 2008.
Table 7 shows the mean time consumption and the
personal costs for the patients in this programme. The total
counselling time per patient varied between 130 and
Table 4 Stop smoking results (n = 145)
6 months
(n = 145)
12 months
(n = 145)
Stop smoking 58 (40%) 48 (33%)
Continued smoking 79 (54%) 60 (41%)
Lost to follow-up 8 (6%) 19 (14%)
Died of disease 5 (3%)
Recurrent disease 13 (9%)
Table 5 Nicotine replacements and smoking cessation results
12 months (n = 108)
Method Continued Smoking
n = 60
Stopped smoking
n = 48
None 10 (17%) 7 (15%)
Nicotine patches 18 (30%) 20 (42%)
Nicotine lozenges 8 (13%) 9 (19%)
Buproprion 2 (3%) 1 (2%)
Combination patches and
lozenges
22 (37%) 9 (19%)
Combination patches and
buproprion
2 (4%)
Table 6 Overview of patients included during the following
3 years after the study period (2003–2005) and their 12-month
smoking cessation rates
Year Patients (n) Stop smoking (%)
2006 89 21
2007 91 31
2008 109 36
Table 7 The various costs for the programme with regards to
counselling time and nicotine replacement; the cost for the counsel-
ling time was derived from Hakkaart-van Roijen et al. [18], and for
the nicotine substitutes from the Pharmacotherapeutic Compass [19]
Units Unit costs €
Counselling
Nurse specialist 183 min 83.85/60 255.74
Nicotine replacement
Nicotine patches 6 pack 17.99 107.94
Nicotine lozenges 1 ﬂacon 22.46 22.46
Buproprion 2.25 months 69.40 156.15
Combi patches and
lozenges
107.94 ? 22.46 130.40
Combi patches and
buproprion
107.94 ? 156.15 264.09
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mean of 183 min per patient, or €255.74. Stated otherwise,
one specialist-nurse in a 1-day per week appointment was
able to manage the total patient cohort. The personal costs
for the patients with regards to the used nicotine replace-
ment patches, lozenges, and/or drugs varied between
€22.46 for the use of one bottle of nicotine lozenges (which
was the minimum) to €264.09 for the full combination of
patches and drugs.
Discussion
The results of the ‘stop smoking clinic’, with smoking
cessation of 40% of the patients at the 6-month interval and
33% at the 12-month interval are quite encouraging. In
general, in the Netherlands the stop smoking results at
1 year are 29% for all adults [1]. While Simon et al. [21]
had similar results (33% after 1 year) with intensive
counselling and the use of free transdermal nicotine
replacement products the smoking cessation rates (of head-
and-neck cancer patients) of Gritz et al. [20] were excep-
tionally much higher, i.e. 70.2% after 1 year. These latter
results most likely have been inﬂuenced by the inclusion of
patients, who were already (less than 1 year) ex-smokers,
and by the fact that 20 patients of the 114 in that study
underwent a total laryngectomy, which makes smoking
difﬁcult or impossible [22]. In our patient cohort, neither
there were total laryngectomy patients, nor did we include
patients spontaneously quitting after their ﬁrst visit to the
clinic and the regular counselling by the physician. This
means that there was a more ‘negative’ patient selection
than in the study of Gritz [20].
An additional positive ﬁnding is that, although the
intention of the stop smoking clinic is to completely stop
and not to only reduce smoking, 24 out of the 60 patients
(40% of this ‘failure’ group), who did not quit smoking,
reported that they reduced their number of cigarettes per
day with 50% or more. This still can be considered a
worthwhile effect of the programme, since e.g. in a study
of Godtfredsen et al. [23] it was demonstrated that reducing
tobacco consumption from 20 to less than 10 cigarettes per
day was associated with a 27% reduction in lung cancer
risk compared with unchanged heavy smoking.
In our study, we did not ﬁnd different smoking cessation
results between head-and-neck cancer patients and lung
cancer patients (both 31%), while Schnoll et al. [8] found a
clear association between the cancer site and the smoking
status: 21% of head-and-neck cancer patients versus 78%
of lung cancer patients quit smoking in their study. An
explanation for this difference might be that the lung
cancer patients in our study mostly had disseminated dis-
ease and received palliative treatment. Most likely, this has
reduced their motivation to quit smoking. Like Ostroff
et al. [9], we did not ﬁnd a correlation between the number
of ‘smoking-years’, nor the daily consumption of tobacco
and smoking cessation results.
Although our data did not show a statistically signiﬁcant
relation between the timing of the enrolment into the
programme (pre-, during or post-treatment) and the actual
smoking cessation rate, we still agree with Gritz et al. [20]
that patients should start such a stop smoking programme
as early as possible, i.e. preferably at the time of diagnosis.
These authors stated that ‘‘the diagnosis and treatment
period of head-and-neck cancer offer an opportune time for
intervention, a ‘‘teachable moment’’, when presumably
there is a high motivation for cure and prevention of further
disease’’. Furthermore, Wewers et al. [24] reported that the
diagnostic testing period for lung cancer is a good moment
for promoting smoking abstinence. In addition, Rigotti
et al. [25] concluded that smoking cessation interventions
conducted with hospitalised patients were effective only
when the outpatient follow-up period lasted for at least
1 month. Moreover, the study of Chen et al. [7] underlines
that tobacco smoking during radiation therapy for head-
and-neck cancer was associated with unfavourable out-
comes, which is an additional reason to confront the patient
as early as possible with smoking cessation. In contrast,
patients who have completed their treatment might be
tempted to minimise the seriousness of their diagnosis and,
thus, might be less committed to quitting [8].
In our study patients, who had one or more earlier
attempts to quit, have signiﬁcantly better smoking cessa-
tion results. This is in agreement with Chan et al. [26], who
in a multivariable modelling procedure showed that the
number of attempts to quit smoking was signiﬁcantly and
independently related to smoking cessation. In addition, as
stated by the US Public Health Service Clinical Practice
Guideline update of 2008 [17]: ‘‘Tobacco dependence is a
chronic disease that often requires repeated intervention
and multiple attempts to quit’’.
Prospective studies often show that motivation to quit
smoking is a consistent predictor of smoking cessation and
treatment studies show that initial ‘quit-motivation’ pre-
dicts success in a smoking intervention [23, 27]. However,
in our study the motivation status of the patient at the start
of the programme, assessed with a single item question in
the Stivoro structured questionnaire (a little to very moti-
vated) did not appear to be a signiﬁcant factor in the stop
smoking results. Probably, this single item question does
not reﬂect the real motivation of the patient and only
results in a socially acceptable answer.
Of the 12-month follow-up cohort, the vast majority of
patients had used some kind of nicotine replacement, and
that probably explains why no statistically signiﬁcant
association between the use of nicotine replacement
Eur Arch Otorhinolaryngol (2012) 269:659–665 663
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This is in contrast to other studies, e.g. according to Ha-
tsukami et al. [11] the combination of nicotine patches and
the use of ad libitum nicotine lead to better efﬁcacy than
single products. In addition, the US Public Health Service
Clinical Practice Guideline states that the combination of
counselling and medication is more effective than either
alone [17]. Presently, more anti-smoking drugs are
available than at the start of the stop smoking clinic, and
even nicotine vaccination (http:\\www.hag.unimaas.nl/
nicotinevaccinstudie/UK/Home.htm) presently is trialled
to support smoking cessation. Possibly these will further
improve the results in stop smoking studies in the future.
Interestingly, our data did neither show an association
between alcohol use and smoking cessation, nor with the
patient’s partner smoking behaviour (continue or also try-
ing to quit), or the extent of support by family and/or
friends. This is in contrast with Schnoll et al. [8], who
stated that having a family member at home who smokes
increased the likelihood that patients will continue to
smoke. They recommend recruiting the patient’s relatives,
who smoke into the cessation programme. In our pro-
gramme we also gave the relatives/partner advice how to
help the patient with his/her attempts to stop smoking, and
if the relatives/partner also wanted to quit smoking, they
could follow the programme together with the patient.
Maybe that is what they did and why we consequently did
not see any inﬂuence of the relatives/partner smoking
behaviour and the smoking cessation results of the patient.
Finally, like Ostroff et al. [9], we neither found a relation
between the number of pack/years nor with the daily
consumption of tobacco and the smoking cessation results.
A limitation in this study is the subjectivity of the data
regarding smoking status, which is based solely on
patients’ self-report (questionnaires). Biochemical veriﬁ-
cation of self-reported smoking status via cotinine assays
would strengthen the study ﬁndings. However, many
quality of life studies report that smoking and alcohol
habits of patients can be assessed correctly by means of
questionnaires, but when it comes to the number of ciga-
rettes or the amount of alcohol units per day you may
assume that those self-reports are probably not reliable [9].
Another limitation of this study is that the study design
and the data collected did not allow for a meaningful cost-
effectiveness analysis. However, we think that quite likely
the average counselling costs of €255,74 per patient out-
weigh the known disadvantages of continued smoking.
Moreover, almost all cessation interventions targeted at
smokers in the general population appear to be cost-
effective [28]. Hoogendoorn et al. [29] e.g. reported that
pharmacotherapy in combination with intensive counsel-
ling was cost saving compared with intensive counselling
alone, and that the latter in turn was more effective than
minimal intervention. These ﬁndings have resulted in the
recent decision as of 2011 in The Netherlands to fully
reimburse smoking cessation treatment programmes under
the compulsory basic health insurance plans. This makes
integration of such programmes in treatment plans obvi-
ously much easier.
In future, this stop smoking programme will be even
more individualised: counselling moments related to highly
and less dependent smokers, more focus on patients who
never tried to quit before. Furthermore, since 2007 not only
patients with head-and-neck cancer and lung cancer are
included in the programme, but also patients with other
types of cancer and e.g. patients requiring free ﬂap surgery.
Conclusion
This nurse-managed smoking cessation programme for
patients with head and neck or lung cancer, who were not
able to stop despite speciﬁc counselling of their health-care
providers before the onset of treatment, shows favourable
results. Despite this negative selection, the long-term ces-
sation rates seem even somewhat better than those
achieved with comparable programmes for non-cancer
patients in the Netherlands. The only signiﬁcant factor for
success appeared to be whether patients had made earlier
attempts to stop smoking before entering in this pro-
gramme. It seems logical, therefore, to integrate such a
programme in treatment protocols for smoking-related
cancers.
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